当前位置:
X-MOL 学术
›
Mol. Pharmaceutics
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
pH and Redox Dual Responsive Nanoparticle for Nuclear Targeted Drug Delivery
Molecular Pharmaceutics ( IF 4.5 ) Pub Date : 2012-08-22 00:00:00 , DOI: 10.1021/mp300274g Remant Bahadur K. C. 1 , Bindu Thapa 1 , Peisheng Xu 1, 2, 3
Molecular Pharmaceutics ( IF 4.5 ) Pub Date : 2012-08-22 00:00:00 , DOI: 10.1021/mp300274g Remant Bahadur K. C. 1 , Bindu Thapa 1 , Peisheng Xu 1, 2, 3
Affiliation
To mimic the clinic dosing pattern, initially administering high loading dose and then low maintenance dose, we designed a novel poly(2-(pyridin-2-yldisulfanyl)ethyl acrylate) (PDS) based nanoparticle delivery system. Side chain functional PDS was synthesized by free radical polymerization. Polyethylene glycol and cyclo(Arg-Gly-Asp-d-Phe-Cys) (cRGD) peptide was conjugated to PDS through thiol–disulfide exchange reaction to achieve RPDSG polymer. RPDSG/DOX, RPDSG nanoparticle loaded with doxorubicin, was fabricated by cosolvent dialysis method. The size of the nanoparticles was 50.13 ± 0.5 nm in PBS. The RPDSG/DOX nanoparticle is stable in physiological condition while quickly releasing doxorubicin with the trigger of acidic pH and redox potential. Furthermore, it shows a two-phase release kinetics, providing both loading dose and maintenance dose for cancer therapy. The conjugation of RGD peptide enhanced the cellular uptake and nuclear localization of the RPDSG/DOX nanoparticles. RPDSG/DOX exhibits IC50 close to that of free doxorubicin for HCT-116 colon cancer cells. Due to the synergetic effect of RGD targeting effect and its two-phase release kinetics, RPDSG/DOX nanoparticles display significantly higher anticancer efficacy than that of free DOX at concentrations higher than 5 μM. These results suggest that RPDSG/DOX could be a promising nanotherapeutic for tumor-targeted chemotherapy.
中文翻译:
pH和氧化还原双重响应纳米粒子的核靶向药物输送。
为了模拟临床给药模式,首先要给予高负荷剂量,然后再给予低维持剂量,我们设计了一种新型的基于聚(2-(吡啶-2-基二硫烷基)丙烯酸乙酯)(PDS)的纳米颗粒输送系统。通过自由基聚合合成侧链功能性PDS。聚乙二醇和环(Arg-Gly-Asp- d-Phe-Cys)(cRGD)肽通过硫醇-二硫键交换反应与PDS偶联,获得RPDSG聚合物。通过共溶剂渗析法制备了载有阿霉素的RPDSG纳米颗粒RPDSG / DOX。在PBS中,纳米颗粒的尺寸为50.13±0.5nm。RPDSG / DOX纳米颗粒在生理条件下稳定,同时在酸性pH和氧化还原电位的触发下快速释放阿霉素。此外,它显示了两相释放动力学,为癌症治疗提供了加载剂量和维持剂量。RGD肽的缀合增强了RPDSG / DOX纳米颗粒的细胞摄取和核定位。RPDSG / DOX展示IC 50与HCT-116结肠癌细胞的游离阿霉素接近。由于RGD靶向作用及其两相释放动力学的协同作用,RPDSG / DOX纳米颗粒在高于5μM的浓度下显示出比游离DOX显着更高的抗癌功效。这些结果表明,RPDSG / DOX可能是针对肿瘤靶向化疗的有前途的纳米疗法。
更新日期:2012-08-22
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
pH和氧化还原双重响应纳米粒子的核靶向药物输送。
为了模拟临床给药模式,首先要给予高负荷剂量,然后再给予低维持剂量,我们设计了一种新型的基于聚(2-(吡啶-2-基二硫烷基)丙烯酸乙酯)(PDS)的纳米颗粒输送系统。通过自由基聚合合成侧链功能性PDS。聚乙二醇和环(Arg-Gly-Asp- d-Phe-Cys)(cRGD)肽通过硫醇-二硫键交换反应与PDS偶联,获得RPDSG聚合物。通过共溶剂渗析法制备了载有阿霉素的RPDSG纳米颗粒RPDSG / DOX。在PBS中,纳米颗粒的尺寸为50.13±0.5nm。RPDSG / DOX纳米颗粒在生理条件下稳定,同时在酸性pH和氧化还原电位的触发下快速释放阿霉素。此外,它显示了两相释放动力学,为癌症治疗提供了加载剂量和维持剂量。RGD肽的缀合增强了RPDSG / DOX纳米颗粒的细胞摄取和核定位。RPDSG / DOX展示IC 50与HCT-116结肠癌细胞的游离阿霉素接近。由于RGD靶向作用及其两相释放动力学的协同作用,RPDSG / DOX纳米颗粒在高于5μM的浓度下显示出比游离DOX显着更高的抗癌功效。这些结果表明,RPDSG / DOX可能是针对肿瘤靶向化疗的有前途的纳米疗法。